Eli Lilly and Company

Merck & Co., Inc.

Regeneron Pharmaceuticals, Inc.

Increased volatility and doubts about AI's prospects have pushed the market toward defensive stocks

Healthcare has become a safe haven for investors: the sector grew by 10% in November

Novo Nordisk A/S

Novo Nordisk reported that its new experimental drug helped people lose weight and improve blood sugar levels in trials. The positive news contributed to the growth of the company's quotations by almost 5%. However, the shares of the Ozempic manufacturer have fallen in price by about 50% this year. Is it worth buying them in hopes of a reversal?

A new drug from the creator of Ozempic has helped people lose weight. Is it time to buy stocks?

The company is starting to resemble the tech giants from "The Magnificent Seven" again, analysts said

Eli Lilly became the first pharma giant to be capitalized at $1 trillion. What's next?

Hims & Hers Health, Inc.

The company is vying for a market that is predicted to grow to $100 billion by the end of the decade

Novo has lowered prices for obesity drugs in the US. This is a new challenge for Eli Lilly

The company struck a deal with the White House last week: its obesity drugs will be included in Medicare coverage

Eli Lilly shares hit a record for the first time in more than a year. Are they worth buying?

Developers of diabetes and obesity drugs Eli Lilly and Novo Nordisk have reached agreements with the administration of US President Donald Trump, the two <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916450">companies</a> <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-and-us-government-agree-expand-access-obesity-medicines">announced on</a> November 6. Under the terms of the deal, the pharmaceutical manufacturers will reduce the prices of their popular drugs.

Lilly and Novo will cut the price of obesity drugs in the US. What will they get in return?

Competition with Eli Lilly and abrupt changes in Novo Nordisk's management are putting pressure on its performance

Ozempic's creator lowered forecasts for the fourth time this year. Should we sell the stock?

Danish Novo Nordisk will release its quarterly report on Nov. 5.

Novo Nordisk's 5 challenges: what's at the center of investment banks' attention 

Viking Therapeutics, Inc.

Shares of biotech company Viking Therapeutics could triple, according to Canaccord Genuity, which in a <a href="https://www.cnbc.com/2025/10/29/biggest-analyst-calls-wednesday-include-nvidia-apple-tesla-datadog.html">coverage initiation</a> called the firm "one of the leading biotech companies in the obesity drug development space," now <a href="https://oninvest.com/article/gde-investoram-iskat-potencial-nyj-hit-na-rynke-preparatov-ot-lisnego-vesa">dominated</a>&nbsp;by Novo Nordisk and Eli Lilly.

Canaccord initiates on obesity drugmaker Viking with 'buy,' sees 200% upside

JPMorgan Chase & Co.

Stryker Corporation

Mastercard Incorporated

Marsh & McLennan Companies, Inc.

Analysts chose companies from a variety of sectors outside of technology

It's not just technology: Morningstar named five popular stocks with top U.S. funds

The retail price of Ozempic, which Trump has called a "weight-loss drug," is about $1,000 for a one-month course

Trump has promised to cut the price of Ozempic to $150. Novo Nordisk and Eli Lilly shares fell

The Coca-Cola Company

Chewy, Inc.

Steve Cohen, founder of hedge fund Point72 Asset Management, believes the current upturn in the markets looks unreliable. He estimates the likelihood of a recession at nearly 45%, and he says indexes could yet return to April lows. "We're all somewhat dependent on news right now, and that's a tricky way to manage money," the investor says.